02883nam a2200289   4500001000800000005001700008007000300025008004100028040000800069041000800077100003100085245008600116300002500202520194400227650003102171650003502202650003302237650003102270700002702301700002402328700002602352700002602378700003102404773011002435942003102545999001702576ESSALUD20260804185551.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aHou, Jinlin eAutor953847  aPhase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection  apáginas: 2395-2406  aBackground: Treatment with bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus (HBV) transcripts, has the potential to result in a functional cure, defined by at least 24 weeks of a sustained HBV DNA level below the lower limit of quantification (LLOQ) and hepatitis B surface antigen (HBsAg) loss after fixed-duration therapy.
Methods: In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcutaneous bepirovirsen (at a weekly dose of 300 mg) or placebo for 24 weeks. All the patients were receiving stable nucleoside or nucleotide analogue (NA) therapy and had an HBsAg level of more than 100 to 3000 IU per milliliter. Eligible patients discontinued NA therapy at 48 weeks. The primary outcome was a functional cure at week 72.
Results: The percentage of patients with a functional cure at week 72 was significantly higher with bepirovirsen than with placebo both in the B-Well 1 trial (in 127 of 650 patients [20%] vs. none of 328 patients) and in the B-Well 2 trial (in 106 of 570 patients [19%] vs. none of 286 patients). In a pooled analysis at 72 weeks, adverse events were reported in 91% of the patients in the bepirovirsen groups and in 73% of those in the placebo groups; serious adverse events were reported in 7% and 4% of the patients, respectively. During the treatment period, adverse events of grade 3 or higher were reported in 16% of the patients who received bepirovirsen and in 3% of those who received placebo; increases in the alanine aminotransferase level were the most common grade 3 adverse events with bepirovirsen (in 6% of the patients).
Conclusions: In two phase 3 trials involving patients with chronic HBV infection, a functional cure after the discontinuation of NA therapy was reported in significantly more patients treated with bepirovirsen than in those who received placebo.   aGASTROENTEROLOGÍA912562  aENFERMEDADES INFECCIOSAS96776  aENFERMEDAD HEPÁTICA953848  aINFECCIONES VIRALES953766  aLim, Seng-Gee  953849  aButi, Maria 953850  aMan-Fung ,Yuen953851  aGane, Edward  953852  aLampertico, Pietro 9538530 022717922639dMassachusetts NEJM GroupoNEJM006tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-07-31zSQB  c22757d22757